Novo Nordisk’s quarterly sales and operating profit beat expectations as its Wegovy pill outperformed forecasts. According to CNBC, the Danish drugmaker also raised its full-year outlook, sending shares as much as 6% higher in early trading.
The Novo earnings recovery gained ground, but the central investor question remains unresolved: whether demand for its existing weight-loss drugs can carry the company while newer products and intense competition reshape the market.
- Third-quarter sales reached 79.2 billion Danish kroner, up 4% at constant exchange rates.
- Adjusted operating profit was 31.7 billion kroner, above the 28.6 billion kroner expected.
- The full-year outlook moved to growth of between negative 2% and positive 2%.
- Wegovy pill sales reached 5.4 billion kroner, versus expectations of about 4.5 billion.
- Shares rose as much as 6% before ending the reported session up 3.4%.
The quarterly numbers improved
Novo reported revenue of 79.2 billion Danish kroner, equivalent to $11.9 billion in the CNBC report. That was above FactSet’s estimate of 73.6 billion kroner. Adjusted operating profit also came in above expectations.
Several important products contributed. Wegovy pill sales were 5.4 billion kroner, comfortably ahead of the roughly 4.5 billion kroner analysts expected. Injectable Wegovy produced 20.4 billion kroner, while diabetes treatment Ozempic generated 29.7 billion kroner. Both also exceeded expectations.
The company revised its full-year outlook for adjusted revenue and operating profit growth to a range of negative 2% to positive 2% at constant exchange rates. Its previous range was negative 6% to flat for both measures.
The difference is important. Novo has moved from expecting a possible full-year decline to projecting a narrower range around no growth. That is improvement, but it is not yet solid expansion.
How Novo reached this point
The Danish company helped establish the GLP-1 weight-loss drug category, which is now used by roughly one in ten Americans. It then faced rapid competition from Eli Lilly, which caught up and surpassed it in the US market.
Investor attention is shifting toward next-generation drugs capable of treating obesity-linked conditions such as heart and kidney disease, sleep apnea and arthritis. Novo is preparing to launch CagriSema, a combination of semaglutide and the long-acting amylin analogue cagrilintide.
Novo has promoted benefits that exceed those of rival treatments, but CNBC reported that analysts have repeatedly questioned the product’s commercial viability after it failed to beat medicines already available from Lilly.
Pricing, competition and the successor pipeline also shape the company’s prospects. Citi maintained a neutral rating on Novo stock because of uncertainty over near-, medium- and long-term weight-loss drug pricing and the lack of a clear Wegovy successor.
Why Novo earnings recovery is incomplete
The case for improvement is stronger because demand, product sales and guidance moved in the same direction. Still, CEO Mike Doustdar warned that a turnaround could not be declared from one good result.
That caution fits the evidence. Novo’s revised guidance permits a modest decline as well as modest growth. The strong Wegovy pill result also raises questions about how quickly patients and prescribers will move beyond injectable formats.
For careers, this offers a useful lesson about assessing a company outside its own sector. Financial strength can rest on several moving parts: market share, product launches, pricing, regulatory progress and the depth of the pipeline. Headline quarterly growth rarely reveals which part is carrying the result.
Consider a candidate interviewing for a commercial role in pharmaceuticals. Novo’s results appear strong at first glance. A sharper interview question would ask which source of growth is repeatable and which depends on a launch schedule.
The response could be tested against the disclosed figures. Existing products, the pill, the improved outlook and CagriSema’s prospects carry different levels of certainty. That turns a generic question about growth into a more concrete discussion of execution and risk.
What to watch next
Watch Novo’s US market position, the response to the Wegovy pill and evidence around CagriSema. Also watch the CFO transition. After spending 27 years with Novo, including nine in the CFO role, Karsten Munk Knudsen is scheduled to exit when 2026 closes. Luigi La Corte of Galderma is set to succeed him.
Novo has shown that one quarter can change the direction of an earnings narrative. It has not shown that the underlying competitive and pricing questions are resolved. The recovery looks real enough to monitor, not secure enough to treat as finished.
Key takeaways
- Sales, operating profit and guidance all moved in Novo’s favour during the quarter.
- The updated outlook still allows for a small full-year decline.
- Wegovy pill demand was strong, but competition and pricing remain unresolved.
- CagriSema and the path beyond Wegovy will shape the next phase of the recovery.
Frequently asked questions
How did Novo Nordisk’s third-quarter sales compare with expectations?
Sales reached 79.2 billion Danish kroner, above the 73.6 billion kroner FactSet estimate cited by CNBC.
Did Novo improve its full-year outlook?
Yes. Adjusted revenue and operating profit growth moved to a range of negative 2% to positive 2%, up from negative 6% to flat.
How strong were Wegovy pill sales?
They totalled 5.4 billion Danish kroner, compared with roughly 4.5 billion kroner expected by analysts.
Why did the CEO avoid declaring a completed turnaround?
Mike Doustdar said a recovery could not be established from one strong quarterly result, pointing to the need for continued improvement.
Who will succeed Novo’s departing CFO?
Luigi La Corte, currently CFO of Galderma, is due to succeed Karsten Munk Knudsen when he leaves at the end of 2026.